ClinicalTrials.gg
RecruitingNCT06177860Updated Jan 5, 2024

Clinical and Atherosclerotic Characteristics of Patients With ACS Associated With Cocaine Use

An observational study in Myocardial Infarction, Acute Coronary Syndrome and Cocaine Use, sponsored by Hospital El Cruce. Recruiting at 1 site in Argentina. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-01-05.

Sponsored by Hospital El Cruce · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Nov 2024, 1 year 11 months ago, but the record still lists the study as recruiting.
  • Started Nov 2023; still recruiting 3 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
400
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 34 studies in Myocardial Infarction with a site in Argentina — 3 open to participants now, 6 under way, 4 of them phase 3. Myocardial Infarction · Argentina.

Started
2023
with 1 other
Observational
7 of 34
2 open now
Registered
33rd of 34
by date
Lead sponsor
2 of 34
Hospital El Cruce

Among the 34 studies in Myocardial Infarction with a site in Argentina, this one is one of 2 that started in 2023, is one of 7 observational ones, and was the 33rd registered.

Myocardial Infarction

2,273 studies on the registry are indexed under Myocardial Infarction; 373 are open to participants now.

Browse Myocardial Infarction studies →

Open to participants now

3 of the 34 studies in Myocardial Infarction with a site in Argentina are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Argentina have not opened yet or have stopped. Only those recruiting at a site in Argentina →

Who these studies take

Of the 256 Myocardial Infarction studies recruiting now, 173 (68%) set no upper age limit and 25 (10%) stop at 75 or younger; 17 take children under 18; 27 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies in Myocardial Infarction with a site in Argentina, or all of them as a file.
02

Study summary

Cocaine use has increased in our country in recent decades. It is associated with cardiovascular events and early atherosclerotic disease. Acute coronary syndrome (ACS) is one of its most frequent and serious manifestations. There is a lack of scientific information on ACS associated with acute and chronic cocaine use in Argentina.

This study aims to describe the socioeconomic, clinical, and coronary angiographic characteristics, as well as the extent of atherosclerotic disease in patients with ACS associated with cocaine use, and to compare them with ACS not associated with cocaine use.

Methods: We propose an observational, analytical, single-center, two-phase study, with a retrospective and a prospective component. Patients with a diagnosis of ACS admitted to the coronary care unit of a high-complexity public hospital will be included. Clinical, biochemical, coronary angiographic, extracoronary atherosclerotic disease extension and prognostic variables will be described. These variables will be compared between patients with cocaine-associated ACS and non-cocaine-associated ACS.

Read the detailed description

General objective:

  • To identify socioeconomic, clinical, electrocardiographic, coronary angiographic, and atherosclerotic disease extent differences between ACS patients with a history of cocaine use and those without cocaine use.

Specific objectives:

To characterize and compare between both groups:

  • Clinical characteristics.
  • Coronary angiographic findings
  • Extent of myocardial damage related and unrelated to ACS.
  • Severe complications during hospitalization (mortality, resuscitated cardiac arrest, arrhythmias, use of IV inotropics and mechanical ventilatory support).
  • Extent of noncoronary vascular disease.

Design:

A quantitative approach will be used, with an observational, analytical, single-center, two-stage design. In the retrospective stage, cases admitted from April 2019 to June 2023 for ACS will be included, based on data collected in the routine practice of the coronary care unit. In the prospective stage, all cases admitted to our institution for ACS from November 1, 2023, to November 2024 will be included.

Inclusion criteria:

  • Age ≥18 years.
  • Hospitalization with a diagnosis of ACS. For the prospective stage, acceptance to participate in the study and informed consent will be added.

Exclusion criteria:

Retrospective stage: patients who were not questioned about cocaine use. Prospective stage: patients who could not be interviewed to determine their history of cocaine use because of their clinical condition.

Procedures:

Two groups will be defined according to the history of cocaine use: cocaine-associated ACS and non-cocaine-associated ACS.

For the retrospective phase, all patients admitted to the coronary unit for ACS in the period established for the study will be reviewed. It is standard practice to ask about cardiovascular risk factors, history of substance use, including cocaine, and other clinical history. We expect to correctly identify cases of ACS associated and not associated with cocaine use.

In all cases included in both stages, the clinical, electrocardiographic, biochemical, and coronary angiographic characteristics and the extent of extra coronary atherosclerotic disease, complications, and prognosis will be described and compared between the two groups.

In the prospective phase of the study, where medically necessary, cardiac magnetic resonance imaging (MRI) will be performed to assess the extent of ACS-related and non-ACS-related myocardial necrosis and edema. Cardiac MRI findings will be compared between groups.

Clinical follow-up will be limited to hospitalization.

Main study variables and measurement instruments:

  • ACS associated with cocaine and other substance use: They will be revealed by questioning, following evidence-based recommendations. ACS associated with cocaine use will be considered for those patients who verbally report the history.
  • Clinical variables: Will be recorded on admission: age, weight and height, blood pressure, heart rate, cardiovascular risk factors (hypertension, diabetes, dyslipidemia, smoking), use of other substances (marijuana, using the same criteria as for cocaine), cardiovascular history (myocardial infarction, stroke, coronary revascularization, peripheral vascular disease, and heart failure).
  • Electrocardiographic variables: 12-lead electrocardiograms will be performed on admission and during hospitalization to classify ACS as ST-elevation myocardial infarction (STEMI) or non-ST-elevation acute coronary syndrome (NSTEMI), to describe the location of ACS and to detect complications.
  • Biochemical: a general and specific biochemical evaluation of ACS (CPK, CK mb, troponin, Pro BNP) will be performed. Peak enzymatic elevation of CPK and troponins will be used as a biochemical indicator of the extent of myocardial necrosis.
  • Echocardiography: an assessment of ventricular function will be performed by measuring ejection fraction, diastolic dysfunction, and wall motility disorders. The presence of mechanical complications will be evaluated by this method.
  • Extent and complexity of coronary atherosclerotic disease: coronary angiography will be used to define the extent and complexity of coronary lesions using the SYNTAX score. Also, an assessment of acute pathophysiological mechanisms related to ACS (thrombus, spasm, coronary dissection, as dichotomous variables: present or absent) will be performed.
  • Extent of extra coronary atherosclerotic disease: ankle-brachial index (ABI) will be used as an indicator of peripheral vascular disease of the lower limbs. The presence, morphology, and extent of atherosclerotic plaque at the carotid level will be determined by carotid Doppler ultrasound.
  • MRI: the degree of myocardial necrosis and edema related and unrelated to ACS will be assessed, as a manifestation of acute and chronic myocardial damage associated with ACS and cocaine use.

Statistical analysis:

Continuous variables will be described as mean and standard deviation in the case of normal distribution or median and interquartile range, and categorical variables will be described as numbers and percentages. Differences between groups for continuous variables will be evaluated with the T-test for variables with a normal distribution, and the Kruskal-Wallis test for nonparametric variables. Categorical variables will be compared using the chi-squared test and Fisher's exact test. Multiple logistic regression models will be developed to determine the independent association between cocaine use and the dependent variables of interest. Statistical analysis will be performed with the R Studio program.

Procedures to ensure the ethical aspects of the research:

All study procedures will be conducted following international ethical norms and standards to respect participant's rights and protect confidentiality.

In addition, all study procedures conform to the principles of the Declaration of Helsinki and CIOMS guidelines.

The research protocol was submitted for evaluation and approved by the Research Ethics Committee (REC) of the El Cruce Hospital.

For the retrospective stage, the research team will make every effort to contact patients who meet the inclusion criteria to request informed consent for their data to be analyzed, undertaking to guarantee the anonymity of personal data. For the prospective stage of the study, potentially eligible individuals will receive a detailed explanation of the objectives and procedures before enrollment. They will be asked to sign the informed consent form (ICF). Participation is voluntary and anonymity and confidentiality of information are compromised. At this stage, only cases that have signed the ICF will be included.

All information related to the study will be securely archived with access codes only available to the research team. Personal identification records will be kept separately from study records identified by code number. Data collection forms will be coded to maintain participant confidentiality. The local database will be protected with a password-protected access system. Study key codes linking participant identification numbers to other identifying information will be stored in a separate, locked file in a limited access area.

03

Conditions studied

  • Myocardial Infarction
  • Acute Coronary Syndrome
  • Cocaine Use
  • Cocaine Abuse

Keywords

  • Myocardial infarction
  • Acute Coronary Syndrome
  • Cocaine Use
  • Cocaine Abuse
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with acute coronary syndrome admitted to the coronary care unit of a high-complexity hospital.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18
  • Hospitalization due to diagnosis of ACS, made by the treating medical team.

For the prospective stage, it will be added:

  • Acceptance to participate in the study and willingness to sign the .

Exclusion criteria

Exclusion Criteria:

  • Patients who, due to their clinical condition, cannot be interviewed to determine their history of cocaine use.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
400 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Complexity and extent of coronary heart disease

    The Syntax Score (Synergy Between PCI With Taxus and Cardiac Surgery) will be quantified in patients with and without a history of cocaine use. A higher Syntax Score indicates a more complex coronary disease as well as worse prognosis. Score values of 0 to 22 are considered low complexity, 23 to 32 moderate complexity and \>32 high complexity.

    Time frame: During coronary angiography

  2. Clinical presentation as STEAMI, or NSTEAMI or unstable angina

    Differences between groups in clinical presentation as STEAMI, NSTEAMI or unstable angina will be based on the findings of the first electrocardiogram registred during admision, following the Fourth Universal Definition of Myocardial Infarction.

    Time frame: Up to 24 hours of admission

  3. Mortality

    Total mortality

    Time frame: During hospitalization (up to 30 days)

  4. Severe complications

    A combined ouctome including: resuscitated cardiac arrest, complex arrhythmia requiring electrical cardioversion, use of inotropes, or mechanical ventilatory support.

    Time frame: During hospitalization (up to 30 days)

Secondary outcomes

  1. Extent of atherosclerotic vascular disease

    The extent of extracoronary atherosclerotic vascular disease will be quantified by vascular Doppler of the carotids and lower limbs

    Time frame: During hospitalization (up to 30 days)

  2. Myocardial damage

    The extent of ischemic and non-ischemic myocardial damage will be quantified by cardiac MRI.

    Time frame: During hospitalization (up to 30 days)

  3. Socioeconomic factors: unemployment

    Unemployment (as a proportion) will be compared between patients with and without a history of cocaine use.

    Time frame: During hospitalization (up to 30 days)

  4. Socioeconomic factors: health insurance

    Health insurance ownership (as a proportion) will be compared between patients with and without a history of cocaine use.

    Time frame: During hospitalization (up to 30 days)

  5. Socioeconomic factors: highest level of formal education

    The highest level of formal education (as an ordinal variable from kindergarten = 1 to college = 8) will be compared between patients with and without a history of cocaine use.

    Time frame: During hospitalization (up to 30 days)

07

Study locations

1 of 1 sites recruiting
  • Hospital El Cruce
    Florencio Varela, Buenos Aires 1888, Argentina
    Recruiting
    • Maximiliano de Abreu, PhD · Contactmaxideabreu@gmail.com · +5491156577631
    • Ezequiel Lerech, MD · Contactezequiellerech@gmail.com · 5491151336293
    • Maximiliano de Abreu, PhD · Principal investigator
    • Ezequiel Lerech, MD · Sub investigator
    • Santiago Torrroba, MD · Sub investigator
    • Juan Bacigalupe, MD · Sub investigator
    • Mauro Rossi Prat, MD · Sub investigator
    • Diego Kyle, MD · Sub investigator
    • Heraldo D´Imperio, MD · Sub investigator
    • Natalia Vensentini, MD · Sub investigator
    • Graciela Reyes, MD · Sub investigator
    • Pablo Kociubinski, MD · Sub investigator
    • Raúl Solernó, MD · Sub investigator
    • Laura Antonietti, MD · Sub investigator
    • Mariani Javier, MD · Sub investigator
08

References and documents

Publications

  • Kim ST, Park T. Acute and Chronic Effects of Cocaine on Cardiovascular Health. Int J Mol Sci. 2019 Jan 29;20(3):584. doi: 10.3390/ijms20030584. PubMed 30700023 ↗
  • Lange RA, Hillis LD. Cardiovascular complications of cocaine use. N Engl J Med. 2001 Aug 2;345(5):351-8. doi: 10.1056/NEJM200108023450507. No abstract available. Erratum In: N Engl J Med 2001 Nov 8;345(19):1432. PubMed 11484693 ↗
  • Gatto L, Frati G, Biondi-Zoccai G, Versaci F. Cocaine and acute coronary syndromes: Novel management insights for this clinical conundrum. Int J Cardiol. 2018 Jun 1;260:16-17. doi: 10.1016/j.ijcard.2018.03.011. No abstract available. PubMed 29622433 ↗
  • Rezkalla SH, Kloner RA. Cocaine-induced acute myocardial infarction. Clin Med Res. 2007 Oct;5(3):172-6. doi: 10.3121/cmr.2007.759. PubMed 18056026 ↗
  • DeFilippis EM, Singh A, Divakaran S, Gupta A, Collins BL, Biery D, Qamar A, Fatima A, Ramsis M, Pipilas D, Rajabi R, Eng M, Hainer J, Klein J, Januzzi JL, Nasir K, Di Carli MF, Bhatt DL, Blankstein R. Cocaine and Marijuana Use Among Young Adults With Myocardial Infarction. J Am Coll Cardiol. 2018 Jun 5;71(22):2540-2551. doi: 10.1016/j.jacc.2018.02.047. Epub 2018 Mar 10. PubMed 29535062 ↗
  • Ma I, Genet T, Clementy N, Bisson A, Herbert J, Semaan C, Bouteau J, Angoulvant D, Ivanes F, Fauchier L. Outcomes in patients with acute myocardial infarction and history of illicit drug use: a French nationwide analysis. Eur Heart J Acute Cardiovasc Care. 2021 Dec 6;10(9):1027-1037. doi: 10.1093/ehjacc/zuab073. PubMed 34453835 ↗
  • Aquaro GD, Gabutti A, Meini M, Prontera C, Pasanisi E, Passino C, Emdin M, Lombardi M. Silent myocardial damage in cocaine addicts. Heart. 2011 Dec;97(24):2056-62. doi: 10.1136/hrt.2011.226977. Epub 2011 Jun 20. Erratum In: Heart. 2011 Dec;97(24):2061. PubMed 21690608 ↗
  • US Preventive Services Task Force; Krist AH, Davidson KW, Mangione CM, Barry MJ, Cabana M, Caughey AB, Curry SJ, Donahue K, Doubeni CA, Epling JW Jr, Kubik M, Ogedegbe G, Pbert L, Silverstein M, Simon MA, Tseng CW, Wong JB. Screening for Unhealthy Drug Use: US Preventive Services Task Force Recommendation Statement. JAMA. 2020 Jun 9;323(22):2301-2309. doi: 10.1001/jama.2020.8020. PubMed 32515821 ↗

Individual participant data

Plan to share: Undecided — It hasn't been decided yet

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2023 (actual). Primary completion is estimated for Nov 2024, 12 months after the start.

Of 298 non-industry observational studies under Myocardial Infarction, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 140. This study's planned 12 months is below that.

Counting every sponsor, half of 335 studies reached it within 48 months; a quarter within 18 and three quarters within 114.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 29, 2023
First posted
Dec 20, 2023
StartActual
Nov 17, 2023
Primary completionEst.
Nov 30, 2024
CompletionEst.
Nov 30, 2024
Last update
Jan 5, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06177860
Lead sponsor
Hospital El Cruce
Responsible party
Maximiliano de Abreu (Principal Investigator, Hospital El Cruce) — Principal investigator
First posted
Dec 20, 2023
Start date
Nov 17, 2023
Primary completion
Nov 30, 2024 (estimated)
Completion
Nov 30, 2024 (estimated)
Last update
Jan 5, 2024

Study contacts

Maximiliano de Abreu, PhD
Contact
maxideabreu@gmail.com
5491156577631
Ezequiel Lerech, MD
Contact
ezequiellerech@gmail.com
5491151336293
Maximiliano de Abreu, PhD
principal investigator · Hospital El Cruce

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion